Organization
BioNTech Cell & Gene Therapies
1 clinical trial
1 abstract
Clinical trial
Phase I/IIa, First-in-human (FIH), Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of CLDN6 CAR-T With or Without CLDN6 RNA-LPX in Patients With CLDN6-positive Relapsed or Refractory Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2027-01-01
Abstract
CLDN6 CAR-T cell therapy of relapsed/refractory solid tumors ± a CLDN6-encoding mRNA vaccine: Dose escalation data from the BNT211-01 phase 1 trial using an automated product.Org: Friedrich-Alexander University Erlangen-Nuremberg, Netherlands Cancer Institute, Hannover Medical School, University Hospital Hamburg Eppendorf, University Medical Center Mainz,